Glucagon-like peptide-1 (GLP-1) peptides have emerged as a compelling therapeutic avenue for managing metabolic disorders. These naturally occurring hormones are secreted by the gut in response to meal intake, stimulating insulin secretion and suppressing glucagon secretion. GLP-1 agents demonstrate promising therapeutic outcomes in treating type 2